Enzymatica AB Share Price Nasdaq Stockholm
Equities
SE0003943620
Pharmaceuticals
Sales 2024 * | 6.04M 66.11M 504M | Sales 2025 * | 11.85M 130M 988M | Capitalization | 48.71M 533M 4.06B |
---|---|---|---|---|---|
Net income 2024 * | -5M -54.7M -417M | Net income 2025 * | -1M -10.94M -83.38M | EV / Sales 2024 * | 8.59 x |
Net Debt 2024 * | 3.18M 34.82M 265M | Net cash position 2025 * | 2.05M 22.45M 171M | EV / Sales 2025 * | 3.94 x |
P/E ratio 2024 * |
-16.5
x | P/E ratio 2025 * |
-35.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 34.79% |
Managers | Title | Age | Since |
---|---|---|---|
Ulf Thomas Blom
FOU | Founder | 59 | 01/07/01 |
Claus Egstrand
CEO | Chief Executive Officer | 63 | 18/17/18 |
Director of Finance/CFO | 55 | 01/18/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bengt Baron
CHM | Chairman | 62 | 19/16/19 |
Director/Board Member | 56 | 15/16/15 | |
Director/Board Member | 57 | 01/21/01 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |